强生公司向欧洲药品管理局提交申请，寻求AKEEGA的适应症扩展，以治疗患有转移性激素敏感性前列腺癌和HRR基因变异的成年患者

https：//www.jnj.com/media-center/press-releases/johnson-johnson-submits-application-to-the-european-medicines-agency-seeing-indication-extension-of-akeega-niraparib-and-abiraterrone-acetate-dual-action-tablet-for-the-tal-tal-tal-tal-tal-tal-tal-depoitation-of-adult-patients-with-metastatic-hormortality-syndic-hormorte-senior-cancer-and-hrr-gene-alations #：~：text=BEERSE%2C%20BELGIUM%20（3%20July%202025，or%2020202025，or%20prednisolone%20for%20the%